Phibro Reports Q4 Earnings with Strong Fiscal Year Performance
Phibro (PAHC) reported strong financial results for the fiscal year ending in August 2026. The company achieved $1.5 billion in net sales, a 17% increase driven by its acquisition of a medicated feed additive portfolio. Adjusted EBITDA rose to $255 million, up 39%, due to improved operating efficiencies and asset integration. The Animal Health segment led with revenue of $1.16 billion (up 21%), while the Mineral Nutrition Segment grew by 11% to $282.3 million on increased demand for trace minerals like zinc and copper. Vaccine sales reached $156.4 million, up 14%, supported by strong poultry product demand in Latin America and Israel. Phibro also raised guidance for fiscal year 2027 with expected net sales between $1.55 billion to $1.60 billion (midpoint growth of 4%) and adjusted EBITDA projected at $258 million to $268 million.
Topics: ebitda financial_results revenue_growth segment_performance